Lumos Diagnostics Holdings Limited

ASX:LDX Stock Report

Market Cap: AU$26.8m

Lumos Diagnostics Holdings Past Earnings Performance

Past criteria checks 0/6

Lumos Diagnostics Holdings's earnings have been declining at an average annual rate of -7.3%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 0.9% per year.

Key information

-7.3%

Earnings growth rate

39.2%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate0.9%
Return on equity-120.9%
Net Margin-77.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Lumos Diagnostics Holdings Limited (ASX:LDX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Nov 28
Lumos Diagnostics Holdings Limited (ASX:LDX) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Lumos Diagnostics Holdings Limited (ASX:LDX) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

Oct 14
Lumos Diagnostics Holdings Limited (ASX:LDX) Stock Catapults 35% Though Its Price And Business Still Lag The Industry

There Is A Reason Lumos Diagnostics Holdings Limited's (ASX:LDX) Price Is Undemanding

Aug 29
There Is A Reason Lumos Diagnostics Holdings Limited's (ASX:LDX) Price Is Undemanding

Take Care Before Diving Into The Deep End On Lumos Diagnostics Holdings Limited (ASX:LDX)

Jan 03
Take Care Before Diving Into The Deep End On Lumos Diagnostics Holdings Limited (ASX:LDX)

The Market Lifts Lumos Diagnostics Holdings Limited (ASX:LDX) Shares 387% But It Can Do More

Jul 04
The Market Lifts Lumos Diagnostics Holdings Limited (ASX:LDX) Shares 387% But It Can Do More

Bearish: Analysts Just Cut Their Lumos Diagnostics Holdings Limited (ASX:LDX) Revenue and EPS estimates

Jul 12
Bearish: Analysts Just Cut Their Lumos Diagnostics Holdings Limited (ASX:LDX) Revenue and EPS estimates

Revenue & Expenses Breakdown

How Lumos Diagnostics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:LDX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2411-9120
31 Mar 2410-9110
31 Dec 238-9110
30 Sep 239-9110
30 Jun 2311-9120
31 Mar 2311-25151
31 Dec 2212-41191
30 Sep 2212-43211
30 Jun 2212-46241
31 Mar 2214-34241
31 Dec 2116-23241
30 Sep 2117-19211
30 Jun 2119-15181
31 Mar 2116-12162
31 Dec 2012-9152
30 Sep 209-9132
30 Jun 206-9112
30 Jun 194-541
30 Jun 182-120

Quality Earnings: LDX is currently unprofitable.

Growing Profit Margin: LDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LDX is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.

Accelerating Growth: Unable to compare LDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LDX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.7%).


Return on Equity

High ROE: LDX has a negative Return on Equity (-120.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lumos Diagnostics Holdings Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroBell Potter
Shane StoreyWilsons Advisory and Stockbroking Ltd.